A Randomized, Parallel, Open-label Study to Evaluate Efficacy and Safety Effects Using Mikelan® LA Ophthalmic Solution (OS) 2% Versus Timoptol® XE Ophthalmic Solution (OS) 0.5% in Ocular Hypertension Patients
Sponsor study identifier
interventional
32
1 country
1
Study Start
October 2009
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
August 2010
Actual (reported)Study Completion
August 2010
Actual (reported)The primary objective of the clinical study is to evaluate the efficacy and safety for Mikelan LA eye drops 2% (once per day) of intra-ocular pressure decreased.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
August 2010
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
August 20, 2009
Actual (reported)September 7, 2009
Actual (reported)October 2009
Date type not reportedThis date has not been verified as actual or estimated.
August 2010
Actual (reported)August 2010
Actual (reported)The change value of Intra-Ocular Pressure (IOP) in study group
assessment will be done every month for 2 months for each subject
The change value of IOP between groups
assessment will be done every month for 2 months for each subject
The change percentage of IOP in each group
assessment will be done every month for 2 months for each subject
The change of score of Patient satisfaction in each group
assessment will be done every month for 2 months for each subject
Mikelan LA + Xalatan
Timoptol XE + Xalatan
Experimental: Mikelan, 1 drop/daily, for 8 weeks Active Comparator: Timoptol, 1 drop/daily, for 8 weeks
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
These entries preserve how the registry describes the intervention. Their treatment roles are shown separately from molecular identities.
Grouped treatment entry
carteolol (Mikelan), timolol (Timoptol), latanoprost (Xalatan)
The registry names several treatments. This does not confirm that participants received them together or that they form a single product.
View registry recordTri-Service General Hospital
Taipei, Taiwan
Da-Wen Lu, MD/PhD
Department of Opthalmology/ Tri-Service General Hospital
First Submitted
August 20, 2009
First Posted
September 7, 2009
Study Start
October 2009
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
August 2010
Actual (reported)Efficacy and Safety of Travoprost 0.004% Versus Tafluprost 0.0015% in Patients With Primary Open-angle Glaucoma or Ocular Hypertension
Contact the study team to confirm eligibility.
Study Completion
August 2010
Actual (reported)Last Updated
September 5, 2011
Record last verified: 2011-09
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: